To reduce the number of deaths associated with cigarettes, the Food and Drug Administration (FDA), the American health agency, is ready to hit hard, to the chagrin of the tobacco industry. His latest recommendation made public aims to lower the nicotine content in cigarettes to a level that would not cause addiction. According to the FDA, to reduce tobacco-related mortality, action must be taken upstream by preventing addiction. And this means reducing the nicotine, this psychoactive substance responsible for the physical and psychological dependence of tobacco (sometimes from the first cigarettes).
In people who wish to quit smoking, feelings of lack with associated undesirable disorders (irritability, nervousness, agitation, anxiety, sleep disturbances, depressed mood, intellectual concentration disorders, increased appetite or constipation, etc.) are primarily responsible for the difficulties and failures ofsmoking cessation in the short term, recalls the site tobacco-info-service.
Flavored tobacco products also regulated
Nicotine reduction is part of a larger arsenal designed by the FDA to fight against smoking. This would encourage smokers to switch to “less harmful” tobacco products such as electronic cigarettes. With this in mind, the FDA intends to postpone for several years (to 2021-2022) the entry into force of regulations on cigars and electronic cigarettes. This included the obligation for manufacturers of electronic cigarettes to obtain authorization to market their products, recalls Agence France Presse. Also under consideration are flavors in cigarettes and cigars, which could also be regulated.
This regulatory plan should be the subject of discussions with the actors of the sector even if the intentions of the American health agency are already ticking the tobacco companies.
.@FDATobacco will explore product standards to reduce nicotine levels in cigarettes to non-addictive levels: https://t.co/xatqYIYozPpic.twitter.com/ZqbRxHpCpD
— US FDA (@US_FDA) July 28, 2017
Read also:
Soon a vaccine against nicotine?
Alzheimer’s disease: the trail of nicotine receptors